All In Biotech

Drug Trial Radar · NCT04544436

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 864 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

864

Actual

Start

Nov 26, 2020

Primary completion

Dec 19, 2024

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.

Conditions

  • Multiple Sclerosis

Interventions

  • OcrelizumabDrug

    The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).

  • OcrelizumabDrug

    Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.

  • AntihistamineDrug

    Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

  • MethylprednisoloneDrug

    Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)Time frame: Up to approximately 4 years

Locations

121 sites in 21 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates

    Cullman, Alabama

  • Alabama Neurology Associates

    Homewood, Alabama

  • 21st Century Neurology

    Phoenix, Arizona

  • Profound Research, LLC

    Carlsbad, California

  • Stanford University Medical Center

    Stanford, California

  • Advanced Neurology of Colorado, LLC

    Fort Collins, Colorado

  • Neurology Associates, PA

    Maitland, Florida

  • University of South Florida

    Tampa, Florida

  • American Health Network Institute, LLC

    Avon, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • The NeuroMedical Clinic of Central Louisiana

    Alexandria, Louisiana

  • Maine Medical Center

    Scarborough, Maine

  • Dragonfly Research, LLC

    Wellesley, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Cleveland Clinic Lou Ruvo

    Las Vegas, Nevada

  • Dent Neurological Institute

    Amherst, New York

  • UC Health Neurology

    Dayton, Ohio

  • Oklahoma Medical Research Foundation

    Oklahoma City, Oklahoma

  • Abington Neurological Associates

    Willow Grove, Pennsylvania

  • Tri-State Mountain Neurology

    Johnson City, Tennessee

  • Hope Neurology

    Knoxville, Tennessee

  • Bhupesh Dihenia M.D. P.A.

    Lubbock, Texas

  • Lone Star Neurology of San Antonio

    San Antonio, Texas

  • Evergreen MS Center

    Kirkland, Washington

  • Centro de Especialidades Neurológicas y Rehabilitación - CENyR

    Buenos Aires, Argentina

  • CEMIC

    Buenos Aires, Argentina

  • Centro de Investigaciones Médicas Tucuman

    San Miguel de Tucumán, Argentina

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Hospital Erasme

    Brussels, Belgium

  • Revalidatie en MS Centrum

    Overpelt, Belgium

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • IMV Pesquisa Neurológica

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinica Neurologica

    Joinville, Santa Catarina, Brazil

  • CPQuali Pesquisa Clinica Ltda

    São Paulo, São Paulo, Brazil

  • Recherche Sepmus Inc.

    Greenfield Park, Quebec, Canada

  • Centre de Recherche Saint-Louis

    Lévis, Quebec, Canada

  • Rigshospitalet Glostrup

    Glostrup Municipality, Denmark

  • Groupe Hospitalier Pellegrin

    Bordeaux, France

  • CHU Hopital Gabriel Montpied

    Clermont-Ferrand, France

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.